A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Clinical trial NCT06646276 · RECRUITING

Trial details

NCT number: NCT06646276
Sponsor: Bristol-Myers Squibb
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Extensive-Stage Small Cell Lung Cancer

Start date: 2025-02-25
Primary completion: 2028-04-06
Enrollment: 530

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.